Amsterdam-based argenx partnered with UNP in 2025. Through that deal, which is worth up to $1.5 billion in biobucks, UNP used its macrocyclic peptide delivery platform to generate candidates against undruggable targets chosen by argenx.
Smart ring maker and health tracking company Oura plans to acquire AI virtual primary care company and business partner Counsel Health for $625 million, the health tech companies announced Tuesday.
The Food and Drug Administration took another step toward expanding access to treatments for rare diseases, announcing a new proposal for personalized gene therapies. In the latest draft guidance, regulators focused on treatments designed to correct different mutations in the same disease-causing gene. Often, the individual mutations are so rare that traditional clinical trials are impractical or even impossible.
The sale of the activities related to custom contract development and manufacturing of pharmaceutical substances and products is intended to sharpen Merck’s portfolio in line with its medium- to long-term strategic direction and focus it on innovation-driven businesses with high value-creation potential.
The license agreement sees Boehringer pay $358m upfront to cover six biologic preclinical programmes. Sino is also in line for up to $7bn in milestone-based payments, alongside royalties on sales from any drugs commercialised via the partnership.